On March 22, 2023, at the request of the U.S. Food and Drug Administration (“FDA”), Ascend Laboratories LLC. (“Ascend”) issued a voluntary nationwide recall of certain lots of.
At the request of the FDA, Ascend Laboratories issued a voluntary nationwide recall of Dabigatran Etexilate Capsules, a blood thinner medication, because of potential nitrosamine contamination. Nitrosamines can form in drugs during the manufacturing, packaging, and storing stages.
At the end of each week, the law firm d’Oliveira & Associates compiles a summary of recalls, FDA warnings, market withdrawals and safety alerts that the public should be aware of for their …